Hemodiyaliz hastalarında mortalite ile bazal trombosit lenfosit oranı arasındaki ilişki

Amaç: Bu çalışmada, hemodiyaliz hastalarında trombositlenfosit oranı (PLR) ve nötrofil-lenfosit oranı (NLR) gibi temel parametrelerin mortalite ile ilişkisinin değerlendirilmesi amaçlanmıştır.. Gereç ve Yöntem: Bu çalışmada, 1999-2017 yılları arasında, 3 aydan uzun süre hemodiyalize giren 129 hasta retrospektif olarak değerlendirildi. Hastalar dışlama kriterlerinden sonra, halen diyalize giren (n=66) ve ölen (n=33) olarak 2 gruba ayrıldı. Hastaların hemodiyaliz başlangıç (hemodiyalizden sonraki üçüncü ay) klinik ve laboratuvar kayıtları değerlendirilerek mortalite ile ilişkisi araştırıldı. Bulgular: Hastaların yaş ortalaması 57 ± 18,9 yıl (13-93), % 46,5'i (46) kadın ve ortalama hemodiyaliz süresi 35.02 ± 30.44 ay idi. Kaplan Meier sağkalım analizine göre PLR, sağ kalan hemodiyaliz hastalarına kıyasla ölen hemodiyaliz hastalarında anlamlı olarak daha yüksekti, ancak NLR sağ kalan ya da ölen hemodiyaliz hastalarında farklı değildi. Çok değişkenli Cox regresyon analiz modelinde, mortalite ile ilişkili faktörler PLR ve serum sodyum idi. Sonuç: Bazal PLR ve serum sodyumun mortalite için hassas biyobelirteçler olduğunu söyleyebiliriz. Hemodiyalizin 3. ayındaki bazal PLR, kolay erişilebilir, ucuz ve basit bir belirteç olup takip süresince mortalite göstergesi olabilir.

Relationship between mortality and baseline platelet to lymphocyte ratio in hemodialysis patients

Purpose: The aim of this study was to evaluate baselineparameters including platelet-lymphocyte ratio (PLR) andneutrophil-lymphocyte ratio (NLR) as predictive value formortality in hemodialysis patients.Materials and Methods: In this study 129 patientsundergoing hemodialysis more than 3 months, wereevaluated for survival between 1999 and 2017. In the 3.Month of beginning of hemodialysis clinical andlaboratory parameters of the patients were evaluatedretrospectively. The patients were separated into 2 groupsas dead and living. After 30 excluded patients due to studycriteria, 33 paients of the remaining 99 patients died and66 were still undergoing hemodialysis.Results: The mean age of patients was 57 ± 18.9 years (13-93), 46.5% (46) were female and mean hemodialysisvintage was 35.02 ± 30.44 months. According to KaplanMeier, survival analysis PLR was significantly higher inhemodialysis patients who died compared to survivinghemodialysis patients but NLR was not different inhemodialysis patients who surviving or died. MultivariateCox regression analysis model, correlated factorsassociated with mortality were PLR and serum sodium.Conclusion: Baseline PLR and serum sodium were foundto be sensitive biomarkers for mortality. Baseline 3.hemodialysis month PLR of which is easily accessible,inexpensive and simple, can be a predictor of mortality atfollow up period in hemodialysis patients.

PDF

___

1. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis. 1998;32:112-9.
2. Dummer CD, Thome FS, Veronese FV. Chronic renal disease, inflammation and atherosclerosis: new concepts about an old problem. Rev Assoc Med Bras (1992). 2007;53:446-50.
3. Dai L, Golembiewska E, Lindholm B, Stenvinkel P. End-Stage Renal Disease, Inflammation and Cardiovascular Outcomes. Contrib Nephrol. 2017;191:32-43.
4. Akchurin OM, Kaskel F. Update on inflammation in chronic kidney disease. Blood Purif. 2015;39:84-92.
5. Kalantar-Zadeh K, Stenvinkel P, Pillon L, Kopple JD. Inflammation and nutrition in renal insufficiency. Adv Ren Replace Ther. 2003;10:155-69.
6. Stenvinkel P, Alvestrand A. Inflammation in endstage renal disease: sources, consequences, and therapy. Semin Dial. 2002;15:329-37.
7. Yeun JY, Levine RA, Mantadilok V, Kaysen GA. CReactive protein predicts all-cause and cardiovascular mortality in hemodialysis patients. Am J Kidney Dis. 2000;35:469-76.
8. Qureshi AR, Alvestrand A, Divino-Filho JC, Gutierrez A, Heimburger O, Lindholm B, et al. Inflammation, malnutrition, and cardiac disease as predictors of mortality in hemodialysis patients. J Am Soc Nephrol. 2002;13:28-36.
9. Zhang W, He J, Zhang F, Huang C, Wu Y, Han Y et al. Prognostic role of C-reactive protein and interleukin-6 in dialysis patients: a systematic review and meta-analysis. J Nephrol. 2013;26:243-53.
10. Hsu HC, Tsai WH, Jiang ML, Ho CH, Hsu ML, Ho CK et al. Circulating levels of thrombopoietic and inflammatory cytokines in patients with clonal and reactive thrombocytosis. J Lab Clin Med. 1999;134:392-7.
11. Sayinalp N, Haznedaroglu IC, Ozdemir O, Ozcebe OI, Dundar S, Kirazli S. Interleukin-1 beta and interleukin-6 in clonal versus reactive thrombocytosis. Eur J Haematol. 1995;55:339-40.
12. Tefferi A, Ho TC, Ahmann GJ, Katzmann JA, Greipp PR. Plasma interleukin-6 and C-reactive protein levels in reactive versus clonal thrombocytosis. Am J Med. 1994;97:374-8.
13. Zahorec R. Ratio of neutrophil to lymphocyte counts- -rapid and simple parameter of systemic inflammation and stress in critically ill. Bratisl Lek Listy. 2001;102:5- 14.
14. Ouellet G, Malhotra R, Penne EL, Usvya L, Levin NW, Kotanko P. Neutrophil-lymphocyte ratio as a novel predictor of survival in chronic hemodialysis patients. Clin Nephrol. 2016;85:191-8.
15. Templeton AJ, Ace O, McNamara MG, Al-Mubarak M, Vera-Badillo FE, Hermanns T et al. Prognostic role of platelet to lymphocyte ratio in solid tumors: a systematic review and meta-analysis. Cancer Epidemiol Biomarkers Prev. 2014;23:1204-12.
16. Ozcan Cetin EH, Cetin MS, Aras D, Topaloglu S, Temizhan A, Kisacik HL et al. Platelet to Lymphocyte Ratio as a Prognostic Marker of In-Hospital and Long-Term Major Adverse Cardiovascular Events in ST-Segment Elevation Myocardial Infarction. Angiology. 2016;67:336-45.
17. Ozcan Cetin EH, Cetin MS, Canpolat U, Akdi A, Aras D, Temizhan A et al. Platelet-to-lymphocyte ratio as a novel marker of in-hospital and long-term adverse outcomes among patients with acute pulmonary embolism: A single center large-scale study. Thromb Res. 2017;150:33-40.
18. Jofre R, Rodriguez-Benitez P, Lopez-Gomez JM, Perez-Garcia R. Inflammatory syndrome in patients on hemodialysis. J Am Soc Nephrol. 2006;17:274-80.
19. Sueta D, Hokimoto S, Sakamoto K, Akasaka T, Tabata N, Kaikita K et al. Validation of the high mortality rate of Malnutrition-InflammationAtherosclerosis syndrome: -Community-based observational study. Int J Cardiol. 2017;230:97-102.
20. Zhu J-G, Chen J-B, Cheng B-C, Lee C-H, Long G, Chien Y-S. Association between Extreme Values of Markers of Chronic Kidney Disease: Mineral and Bone Disorder and 5-Year Mortality among Prevalent Hemodialysis Patients. Blood purification. 2018;45:1- 7.
21. Cheung AK, Sarnak MJ, Yan G, Berkoben M, Heyka R, Kaufman A et al. Cardiac diseases in maintenance hemodialysis patients: results of the HEMO Study. Kidney international. 2004;65:2380-9.
22. Baber U, Gutierrez OM, Levitan EB, Warnock DG, Farkouh ME, Tonelli M et al. Risk for recurrent coronary heart disease and all-cause mortality among individuals with chronic kidney disease compared with diabetes mellitus, metabolic syndrome, and cigarette smokers. Am Heart J. 2013;166:373-80 e2.
23. Shlipak MG, Fried LF, Cushman M, Manolio TA, Peterson D, Stehman-Breen C et al. Cardiovascular mortality risk in chronic kidney disease: comparison of traditional and novel risk factors. JAMA. 2005;293:1737-45.
24. Streetz KL, Wustefeld T, Klein C, Manns MP, Trautwein C. Mediators of inflammation and acute phase response in the liver. Cell Mol Biol (Noisy-legrand). 2001;47:661-73.
25. Silverstein DM. Inflammation in chronic kidney disease: role in the progression of renal and cardiovascular disease. Pediatr Nephrol. 2009;24:1445-52.
26. Afsar B, Turkmen K, Covic A, Kanbay M. An update on coronary artery disease and chronic kidney disease. Int J Nephrol. 2014;2014:767424.
27. Cheung AK, Sarnak MJ, Yan G, Dwyer JT, Heyka RJ, Rocco MV, et al. Atherosclerotic cardiovascular disease risks in chronic hemodialysis patients. Kidney Int. 2000;58:353-62.
28. Meuwese CL, Carrero JJ, Stenvinkel P. Recent insights in inflammation-associated wasting in patients with chronic kidney disease. Contrib Nephrol. 2011;171:120-6.
29. Agarwal R. Hypervolemia is associated with increased mortality among hemodialysis patients. Hypertension. 2010;56:512-7.
30. Rodrigues Telini LS, de Carvalho Beduschi G, Caramori JC, Castro JH, Martin LC, Barretti P. Effect of dietary sodium restriction on body water, blood pressure, and inflammation in hemodialysis patients: a prospective randomized controlled study. Int Urol Nephrol. 2014;46:91-7.
31. Pecoits-Filho R, Lindholm B, Stenvinkel P. The malnutrition, inflammation, and atherosclerosis (MIA) syndrome - the heart of the matter. Nephrol Dial Transplant. 2002;17:28-31.
32. Niebauer J, Volk HD, Kemp M, Dominguez M, Schumann RR, Rauchhaus M et al. Endotoxin and immune activation in chronic heart failure: a prospective cohort study. Lancet. 1999;353:1838-42.
33. Owen WF, Jr., Lew NL, Liu Y, Lowrie EG, Lazarus JM. The urea reduction ratio and serum albumin concentration as predictors of mortality in patients undergoing hemodialysis. N Engl J Med. 1993;329:1001-6.
34. Leavey SF, Strawderman RL, Jones CA, Port FK, Held PJ. Simple nutritional indicators as independent predictors of mortality in hemodialysis patients. Am J Kidney Dis. 1998;3:997-1006.
35. Turkmen K, Guney I, Yerlikaya FH, Tonbul HZ. The relationship between neutrophil-to-lymphocyte ratio and inflammation in end-stage renal disease patients. Ren Fail. 2012;34:155-9.
36. Turkmen K, Erdur FM, Ozcicek F, Ozcicek A, Akbas EM, Ozbicer A et al. Platelet-to-lymphocyte ratio better predicts inflammation than neutrophil-tolymphocyte ratio in end-stage renal disease patients. Hemodial Int. 2013;17:391-6.
37. Ahbap E, Sakaci T, Kara E, Sahutoglu T, Koc Y, Basturk T et al. Neutrophil-to-lymphocyte ratio and platelet-tolymphocyte ratio in evaluation of inflammation in end-stage renal disease. Clin Nephrol. 2016;85:199-208.
38. Yaprak M, Turan MN, Dayanan R, Akin S, Degirmen E, Yildirim M et al. Platelet-to-lymphocyte ratio predicts mortality better than neutrophil-tolymphocyte ratio in hemodialysis patients. Int Urol Nephrol. 2016;48:1343-8.
39. Eleftheriadis T, Antoniadi G, Liakopoulos V, Kartsios C, Stefanidis I. Disturbances of acquired immunity in hemodialysis patients. Semin Dial. 2007;20:440-51.
40. Yao Q, Lindholm B, Stenvinkel P. Inflammation as a cause of malnutrition, atherosclerotic cardiovascular disease, and poor outcome in hemodialysis patients. Hemodial Int. 2004;8:118-29.